Id: acc3612
Group: 2sens_supp
Protein: IKKbeta
Gene Symbol: IKBKB
Protein Id: O14920
Protein Name: IKKB_HUMAN
PTM: phosphorylation
Site: Ser181
Site Sequence: ELDQGSLCTSFVGTLQYLAPE
Disease Category: Cancer
Disease: Leukemia
Disease Subtype:
Disease Cellline: KBM–5
Disease Info:
Drug: taxol
Drug Info: Taxol is an anti - cancer drug commonly used in the treatment of various cancers. It can inhibit the growth of cancer cells.
Effect: inhibit
Effect Info: Indirubin enhances TNF- and chemotherapeutic drug paclitaxel-induced apoptosis.
Note:
Score: 5.0
Pubmed(PMID): 16785236
Sentence Index:
Sentence:

Sequence & Structure:

MSWSPSLTTQTCGAWEMKERLGTGGFGNVIRWHNQETGEQIAIKQCRQELSPRNRERWCLEIQIMRRLTHPNVVAARDVPEGMQNLAPNDLPLLAMEYCQGGDLRKYLNQFENCCGLREGAILTLLSDIASALRYLHENRIIHRDLKPENIVLQQGEQRLIHKIIDLGYAKELDQGSLCTSFVGTLQYLAPELLEQQKYTVTVDYWSFGTLAFECITGFRPFLPNWQPVQWHSKVRQKSEVDIVVSEDLNGTVKFSSSLPYPNNLNSVLAERLEKWLQLMLMWHPRQRGTDPTYGPNGCFKALDDILNLKLVHILNMVTGTIHTYPVTEDESLQSLKARIQQDTGIPEEDQELLQEAGLALIPDKPATQCISDGKLNEGHTLDMDLVFLFDNSKITYETQISPRPQPESVSCILQEPKRNLAFFQLRKVWGQVWHSIQTLKEDCNRLQQGQRAAMMNLLRNNSCLSKMKNSMASMSQQLKAKLDFFKTSIQIDLEKYSEQTEFGITSDKLLLAWREMEQAVELCGRENEVKLLVERMMALQTDIVDLQRSPMGRKQGGTLDDLEEQARELYRRLREKPRDQRTEGDSQEMVRLLLQAIQSFEKKVRVIYTQLSKTVVCKQKALELLPKVEEVVSLMNEDEKTVVRLQEKRQKELWNLLKIACSKVRGPVSGSPDSMNASRLSQPGQLMSQPSTASNSLPEPAKKSEELVAEAHNLCTLLENAIQDTVREQDQSFTALDWSWLQTEEEEHSCLEQAS

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 3 Terminated diabetic nephropathy ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 3 Terminated Autosomal dominant polycystic kidney disease ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 3 Terminated pulmonary hypertension ClinicalTrials
IKBKB IMD-1041 Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 2 Unknown status chronic obstructive pulmonary disease ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 2 Completed diabetic nephropathy ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 2 Withdrawn melanoma ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 2 Completed pulmonary arterial hypertension ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 2 Completed chronic kidney disease ClinicalTrials
IKBKB SAR-113945 Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 2 Completed osteoarthritis, knee ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 2 Completed Alport syndrome ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 2 Completed COVID-19 ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 1 Completed neoplasm ClinicalTrials
ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 1 Completed liver disease ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 1 Terminated liver disease ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 1 Completed lymphoid neoplasm ClinicalTrials
ClinicalTrials
IKBKB BARDOXOLONE METHYL Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 1 Terminated pancreatic carcinoma ClinicalTrials
IKBKB SAR-113945 Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 1 Completed osteoarthritis, knee ClinicalTrials
ClinicalTrials
IKBKB SAR-113945 Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor 1 Completed osteoarthritis ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

IKBKB-Ser668
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.067
GBM
HNSC 0.965
LUAD -1.032
LUSC
non_ccRCC
PDAC
UCEC
IKBKB-Ser670
Cancer Intensity
BRCA -2.238
COAD 0.632
HGSC 0.291
ccRCC 0.548
GBM 0.921
HNSC 0.28
LUAD -0.163
LUSC
non_ccRCC
PDAC 0.644
UCEC -0.915
IKBKB-Ser673
Cancer Intensity
BRCA
COAD 1.597
HGSC 0.015
ccRCC
GBM -1.16
HNSC
LUAD
LUSC -0.264
non_ccRCC
PDAC
UCEC -0.189
IKBKB-Ser677
Cancer Intensity
BRCA
COAD -0.707
HGSC 0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
IKBKB-Ser690
Cancer Intensity
BRCA
COAD 0.685
HGSC
ccRCC
GBM 0.63
HNSC -1.679
LUAD 0.534
LUSC
non_ccRCC
PDAC
UCEC -0.17
IKBKB-Ser693
Cancer Intensity
BRCA
COAD -0.022
HGSC
ccRCC
GBM 1.609
HNSC -0.383
LUAD -1.121
LUSC
non_ccRCC
PDAC
UCEC -0.083
IKBKB-Ser695
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.82
HNSC 0.604
LUAD
LUSC -0.482
non_ccRCC -1.78
PDAC 0.095
UCEC 0.744
IKBKB-Thr691
Cancer Intensity
BRCA
COAD 0.702
HGSC -0.152
ccRCC
GBM 0.417
HNSC
LUAD 0.708
LUSC
non_ccRCC
PDAC
UCEC -1.676

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: